Diabetic retinopathy is among the leading causes of legal blindness among the working-age adults worldwide. Anticipated increase in prevalence of diabetes prevalence indicates that diabetic retinopathy will continue to the prevalence of vision loss in the future. Diabetes and diabetes related complications carry heavy economic burden. Estimates also suggest that diabetic retinopathy alone contributes 10% to 42% of direct medical costs, whereas the indirect costs could be much higher. Surgical treatments have been preferred for a long time for diabetic retinopathy treatment at severe stages. Several pharmacological treatments are introduced and many are in development for treating this complication. This report studies the global and regional markets for various diabetic retinopathy treatments currently available.
For the purpose of this study, the global diabetic retinopathy market is assessed for diabetic retinopathy treatment devices and drugs. The devices market is categorized into focal laser treatment, scatter laser treatment and vitrectomy devices. the diabetic retinopathy treatment drugs is studied for aflibercept (Eylea), bevacizumab (Avastin), fluocinolone acetonide (Iluvien), ranibizumab (Lucentis) and triamcinolone acetonide. Global market size and forecast for the mentioned segments for the period 2020-2030 along with corresponding CAGRs for the forecast period 2022-2030 are included in this section.
The market size and forecast for the period 2020-2030 along with the CAGRs for the period 2022-2030 for the mentioned segments are also presented in this study.
Qualitative information sets such as market dynamics (drivers, challenges, future prospects) and market inclination insights are provided in this market assessment report. Tools such as competition assessment and attractive investment proposition are also included in this study for studying the global market competition. The report concludes with company profiles section that highlights key information about the major market players operating in the global diabetic retinopathy market.
In cases of diabetic macular edema, which can occur at any stage of diabetic retinopathy injections of anti-VEGF agents are administered to patients directly into the eye to prevent formation of new blood vessels at the back of the eye. Chief medicines used are ranibizumab and aflibercept. These drugs not only efficiently manage diabetic macular edema, but also are also instrumental in vision improvement. Other intravitreal treatments for diabetic macular edema are Fluocinolone intravitreal implant (Iluvien), Bevacizumab (Avastin) and Triamcinolone acetonide injections. Iluvien form Alimera Sciences, Inc. received FDA approval in 2014 for treating diabetic macular edema in patients who have been previously treated with corticosteroids and did not witness significant rise in intraocular pressure. The drug is also been under trial for treatment of dry age-related macular degeneration.
Gradual rise in prevalence of diabetes and escalating diagnosis of diabetes related complications, favorable reimbursement policies and early introduction of breakthrough treatment modalities are the chief drivers that have allowed North America a dominant position in the diabetic retinopathy market. Extensive penetration of patented drugs such as Lucentis, Eylea, Iluvien and Avastin in the U.S. market has contributed to the clear leadership of North America in this area. Followed by North America, Europe is the second largest market for diabetic retinopathy due to high awareness in healthcare professionals and patients about effective management of diabetes related compilations and swift adoption of new treatments. Countries such as India and China while witnessing phenomenal growth in diabetes prevalence and improving rates of diagnosis will make Asia-Pacific the fastest progressing regional market for diabetic retinopathy treatment. Other factors contributing to the growth of this regional market are growth in healthcare expenditure, improving disposable income and development of healthcare infrastructure to facilitate medical tourism.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
For the purpose of this study, the global diabetic retinopathy market is assessed for diabetic retinopathy treatment devices and drugs. The devices market is categorized into focal laser treatment, scatter laser treatment and vitrectomy devices. the diabetic retinopathy treatment drugs is studied for aflibercept (Eylea), bevacizumab (Avastin), fluocinolone acetonide (Iluvien), ranibizumab (Lucentis) and triamcinolone acetonide. Global market size and forecast for the mentioned segments for the period 2020-2030 along with corresponding CAGRs for the forecast period 2022-2030 are included in this section.
The market size and forecast for the period 2020-2030 along with the CAGRs for the period 2022-2030 for the mentioned segments are also presented in this study.
Qualitative information sets such as market dynamics (drivers, challenges, future prospects) and market inclination insights are provided in this market assessment report. Tools such as competition assessment and attractive investment proposition are also included in this study for studying the global market competition. The report concludes with company profiles section that highlights key information about the major market players operating in the global diabetic retinopathy market.
Devices Segmentation Investigation
Diabetic retinopathy has been treated through devices for a long time, and even after advent of advanced drugs, it considered as the most preferred treatment regime. Laser treatment is often preferred for treating the formation of new blood vessels in the advanced stages of diabetic retinopathy. Laser treatment is often preferred because the new blood vessels formed are often very weak and laser treatment successfully stabilizes the risk of vision loss, though not improve the damaged vision. Quick turnaround time and immediate recovery and effect are the prime factors that lead to high preference for laser treatments. Alike laser treatment, vitrectomy does not cure diabetic retinopathy, but is opted as an effective management mode. Despite the proven efficacy of vitrectomy in diabetic retinopathy management, late diagnosis of condition holds back the growth of this market.In cases of diabetic macular edema, which can occur at any stage of diabetic retinopathy injections of anti-VEGF agents are administered to patients directly into the eye to prevent formation of new blood vessels at the back of the eye. Chief medicines used are ranibizumab and aflibercept. These drugs not only efficiently manage diabetic macular edema, but also are also instrumental in vision improvement. Other intravitreal treatments for diabetic macular edema are Fluocinolone intravitreal implant (Iluvien), Bevacizumab (Avastin) and Triamcinolone acetonide injections. Iluvien form Alimera Sciences, Inc. received FDA approval in 2014 for treating diabetic macular edema in patients who have been previously treated with corticosteroids and did not witness significant rise in intraocular pressure. The drug is also been under trial for treatment of dry age-related macular degeneration.
Gradual rise in prevalence of diabetes and escalating diagnosis of diabetes related complications, favorable reimbursement policies and early introduction of breakthrough treatment modalities are the chief drivers that have allowed North America a dominant position in the diabetic retinopathy market. Extensive penetration of patented drugs such as Lucentis, Eylea, Iluvien and Avastin in the U.S. market has contributed to the clear leadership of North America in this area. Followed by North America, Europe is the second largest market for diabetic retinopathy due to high awareness in healthcare professionals and patients about effective management of diabetes related compilations and swift adoption of new treatments. Countries such as India and China while witnessing phenomenal growth in diabetes prevalence and improving rates of diagnosis will make Asia-Pacific the fastest progressing regional market for diabetic retinopathy treatment. Other factors contributing to the growth of this regional market are growth in healthcare expenditure, improving disposable income and development of healthcare infrastructure to facilitate medical tourism.
Historical & Forecast Period
This report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Diabetic Retinopathy market are as follows:- Research and development budgets of manufacturers and government spending.
- Revenues of key companies in the market segment.
- Number of end users and consumption volume, price and value.
- Geographical revenues generated by countries considered in the report.
- Micro and macro environment factors that are currently influencing the Diabetic Retinopathy market and their expected impact during the forecast period.
- The market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Device Type
- Focal Laser Treatment
- Scatter Laser Treatment
- Vitrectomy Devices
Drug Type
- Aflibercept (Eylea)
- Bevacizumab (Avastin)
- Fluocinolone Acetonide (Iluvien)
- Ranibizumab (Lucentis)
- Triamcinolone Acetonide Injection
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Diabetic Retinopathy market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Diabetic Retinopathy market?
- Which is the largest regional market for Diabetic Retinopathy market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Diabetic Retinopathy market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Diabetic Retinopathy market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Diabetic Retinopathy Market
2.2. Global Diabetic Retinopathy Market, by Device Type, 2021 (US$ Million)
2.3. Global Diabetic Retinopathy Market, by Drug Type, 2021 (US$ Million)
2.4. Global Diabetic Retinopathy Market, by Geography, 2021 (US$ Million)
2.5. Impact of COVID-19
2.6. Attractive Investment Proposition by Geography, 2021
2.7. Competitive Analysis
2.7.1. Market Positioning of Key Diabetic Retinopathy Market Vendors
2.7.2. Strategies Adopted by Diabetic Retinopathy Market Vendors
2.7.3. Key Industry Strategies
3. Diabetic Retinopathy Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Diabetic Retinopathy Market Value, 2020-2030, (US$ Million)
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Market Restraints
3.3.3. Key Challenges
3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter’s Five Force Model
3.6.1. Supplier Power
3.6.2. Buyer Power
3.6.3. Threat of Substitutes
3.6.4. Threat of New Entrants
3.6.5. Competitive Rivalry
3.7. PESTEL Analysis
3.7.1. Political Landscape
3.7.2. Economic Landscape
3.7.3. Technology Landscape
3.7.4. Legal Landscape
3.7.5. Social Landscape
4. Diabetic Retinopathy Market: by Device Type, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Focal Laser Treatment
4.3.2. Scatter Laser Treatment
4.3.3. Vitrectomy Devices
5. Diabetic Retinopathy Market: by Drug Type, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Aflibercept (Eylea)
5.3.2. Bevacizumab (Avastin)
5.3.3. Fluocinolone Acetonide (Iluvien)
5.3.4. Ranibizumab (Lucentis)
5.3.5. Triamcinolone Acetonide Injection
6. North America Diabetic Retinopathy Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Diabetic Retinopathy Market: by Device Type, 2020-2030, USD (Million)
6.3. Diabetic Retinopathy Market: by Drug Type, 2020-2030, USD (Million)
6.4. Diabetic Retinopathy Market: by Region, 2020-2030, USD (Million)
6.4.1. North America
6.4.1.1. U.S.
6.4.1.2. Canada
6.4.1.3. Rest of North America
7. UK and European Union Diabetic Retinopathy Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Diabetic Retinopathy Market: by Device Type, 2020-2030, USD (Million)
7.3. Diabetic Retinopathy Market: by Drug Type, 2020-2030, USD (Million)
7.4. Diabetic Retinopathy Market: by Region, 2020-2030, USD (Million)
7.4.1. UK and European Union
7.4.1.1. UK
7.4.1.2. Germany
7.4.1.3. Spain
7.4.1.4. Italy
7.4.1.5. France
7.4.1.6. Rest of Europe
8. Asia Pacific Diabetic Retinopathy Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Diabetic Retinopathy Market: by Device Type, 2020-2030, USD (Million)
8.3. Diabetic Retinopathy Market: by Drug Type, 2020-2030, USD (Million)
8.4. Diabetic Retinopathy Market: by Region, 2020-2030, USD (Million)
8.4.1. Asia Pacific
8.4.1.1. China
8.4.1.2. Japan
8.4.1.3. India
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Rest of Asia Pacific
9. Latin America Diabetic Retinopathy Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Diabetic Retinopathy Market: by Device Type, 2020-2030, USD (Million)
9.3. Diabetic Retinopathy Market: by Drug Type, 2020-2030, USD (Million)
9.4. Diabetic Retinopathy Market: by Region, 2020-2030, USD (Million)
9.4.1. Latin America
9.4.1.1. Brazil
9.4.1.2. Mexico
9.4.1.3. Rest of Latin America
10. Middle East and Africa Diabetic Retinopathy Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Diabetic Retinopathy Market: by Device Type, 2020-2030, USD (Million)
10.3. Diabetic Retinopathy Market: by Drug Type, 2020-2030, USD (Million)
10.4. Diabetic Retinopathy Market: by Region, 2020-2030, USD (Million)
10.4.1. Middle East and Africa
10.4.1.1. GCC
10.4.1.2. Africa
10.4.1.3. Rest of Middle East and Africa
11. Company Profiles
11.1. Alimera Sciences, Inc
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Pfizer
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Genentech USA, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Sandoz Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Bayer Pharma AG
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Regeneron Pharmaceuticals Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Sirnaomics
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Iridex Corporation
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Lumenis
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Valon Lasers OY
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Other Notable Players
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic InitiativesList of Figures
Figure 1. Global Diabetic Retinopathy Market: Market Coverage
Figure 2. Research Methodology and Data Sources
Figure 3. Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4. Global Diabetic Retinopathy Market: Quality Assurance
Figure 5. Global Diabetic Retinopathy Market, By Device Type, 2021
Figure 6. Global Diabetic Retinopathy Market, By Drug Type, 2021
Figure 7. Global Diabetic Retinopathy Market, By Geography, 2021
Figure 8. Global Diabetic Retinopathy Market, By Device Type, 2021 vs 2030, %
Figure 9. Global Diabetic Retinopathy Market, By Drug Type, 2021 vs 2030, %
Figure 10. U.S. Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 11. Canada Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 12. Rest of North America Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 13. UK Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 14. Germany Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 15. Spain Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 16. Italy Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 17. France Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 18. Rest of Europe Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 19. China Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 20. Japan Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 21. India Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 22. Australia Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 23. South Korea Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 24. Rest of Asia Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 25. Brazil Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 26. Mexico Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 27. Rest of Latin America Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 28. GCC Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 29. Africa Diabetic Retinopathy Market (US$ Million), 2020-2030
Figure 30. Rest of Middle East and Africa Diabetic Retinopathy Market (US$ Million), 2020-2030List of Tables
Table 1 Global Diabetic Retinopathy Market by Device Type, 2020-2030, USD (Million)
Table 2 Global Diabetic Retinopathy Market by Drug Type, 2020-2030, USD (Million)
Table 3 North America Diabetic Retinopathy Market by Device Type, 2020-2030, USD (Million)
Table 4 North America Diabetic Retinopathy Market by Drug Type, 2020-2030, USD (Million)
Table 5 UK and European Union Diabetic Retinopathy Market by Device Type, 2020-2030, USD (Million)
Table 6 UK and European Union Diabetic Retinopathy Market by Drug Type, 2020-2030, USD (Million)
Table 7 Asia Pacific Diabetic Retinopathy Market by Device Type, 2020-2030, USD (Million)
Table 8 Asia Pacific Diabetic Retinopathy Market by Drug Type, 2020-2030, USD (Million)
Table 9 Latin America Diabetic Retinopathy Market by Device Type, 2020-2030, USD (Million)
Table 10 Latin America Diabetic Retinopathy Market by Drug Type, 2020-2030, USD (Million)
Table 11 Middle East and Africa Diabetic Retinopathy Market by Device Type, 2020-2030, USD (Million)
Table 12 Middle East and Africa Diabetic Retinopathy Market by Drug Type, 2020-2030, USD (Million)
Companies Mentioned
- Alimera Sciences Ltd
- Pfizer
- Genentech USA Ltd.
- Sandoz Inc.
- Bayer Pharma AG
- Regeneron Pharmaceuticals Inc.
- Sirnaomics
- Iridex Corporation
- Lumenis
- Valon Lasers OY
